Agilent Posts 32 Percent Jump in Q2 Revenues, Strong LC and Mass Spec Sales
May 13, 2011
Agilent Posts 32 Percent Jump in Q2 Revenues, Strong LC and Mass Spec Sales
Sales of the company's mass spec and LC platforms grew by more than 20 percent, as Life Science revenues rose to $464 million from $334 million a year ago.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Agilent Expands Indian Research Facility, Making it Company's Largest Worldwide
March 25, 2011 / ProteoMonitor - New Bruker Mass Spec Machine Leads Product Releases at Quiet Pittcon 2011
March 18, 2011 / ProteoMonitor - Agilent Posts 19 Percent Jump in Q1 Life Sciences Revenues Driven by LC, Mass Spec Sales
February 18, 2011 / ProteoMonitor - Instrument Vendors Focus on UPLC and Triple-Quad, Qual-Quan MS at JP Morgan Conference
January 14, 2011 / ProteoMonitor - Waters, Bruker Report Double-Digit Mass Spec Revenue Growth in Q2
July 30, 2010 / ProteoMonitor